{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:15:44Z","timestamp":1732770944240,"version":"3.29.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.7759\/cureus.74542","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:17:19Z","timestamp":1732688239000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Bisphosphonates in Reducing Fracture Risk Among Postmenopausal Women With Osteoporosis"],"prefix":"10.7759","author":[{"given":"Mutea","family":"Ullah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junaid","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzma","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehriyar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anum","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsalan","family":"Zeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maham","family":"Majid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092382","article-title":"Secondary osteoporosis and metabolic bone diseases","volume":"11","author":"Sobh MM","year":"2022","unstructured":"Sobh MM, Abdalbary M, Elnagar S, et al.. Secondary osteoporosis and metabolic bone diseases. J Clin Med. 2022, 11:2382. 10.3390\/jcm11092382","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell R","year":"2016","unstructured":"Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016, 2:16069. 10.1038\/nrdp.2016.69","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"S\u00f6zen T","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2017, 4:46-56. 10.5152\/eurjrheum.2016.048","journal-title":"Eur J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11430858","article-title":"Aging and bone loss: new insights for the clinician","volume":"4","author":"Demontiero O","year":"2012","unstructured":"Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis. 2012, 4:61-76. 10.1177\/1759720X11430858","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-1637(02)00045-4","article-title":"Hip fractures among the elderly: causes, consequences and control","volume":"2","author":"Marks R","year":"2003","unstructured":"Marks R, Allegrante JP, MacKenzie CR, Lane JM. Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev. 2003, 2:57-93. 10.1016\/S1568-1637(02)00045-4","journal-title":"Ageing Res Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.146","article-title":"Antiresorptive therapies for osteoporosis: a clinical overview","volume":"8","author":"Chen JS","year":"2011","unstructured":"Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2011, 8:81-91. 10.1038\/nrendo.2011.146","journal-title":"Nat Rev Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.05.005","article-title":"Pharmacological diversity among drugs that inhibit bone resorption","volume":"22","author":"Russell RG","year":"2015","unstructured":"Russell RG. Pharmacological diversity among drugs that inhibit bone resorption. Curr Opin Pharmacol. 2015, 22:115-30. 10.1016\/j.coph.2015.05.005","journal-title":"Curr Opin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.6745","article-title":"Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials","volume":"1","author":"Deardorff WJ","year":"2022","unstructured":"Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Internal Med. 2022, 1:33-41. 10.1001\/jamainternmed.2021.6745","journal-title":"JAMA Internal Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0439-3","article-title":"Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women","volume":"13","author":"Yusuf AA","year":"2018","unstructured":"Yusuf AA, Cummings SR, Watts NB, et al.. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos. 2018, 13:33. 10.1007\/s11657-018-0439-3","journal-title":"Arch Osteoporos"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1136287","article-title":"Safety issues and adverse reactions with osteoporosis management","volume":"15","author":"Rossini M","year":"2016","unstructured":"Rossini M, Adami G, Adami S, Viapiana O, Gatti D. Safety issues and adverse reactions with osteoporosis management. Expert Opin Drug Saf. 2016, 15:321-32. 10.1517\/14740338.2016.1136287","journal-title":"Expert Opin Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla S","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, et al.. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012, 97:2272-82. 10.1210\/jc.2012-1027","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4806-0","article-title":"Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study","volume":"30","author":"Bliuc D","year":"2019","unstructured":"Bliuc D, Tran T, van Geel T, et al.. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporos Int. 2019, 30:817-28. 10.1007\/s00198-018-4806-0","journal-title":"Osteoporos Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25190","article-title":"Bisphosphonate treatment beyond 5 years and hip fracture risk in older women","volume":"3","author":"Izano MA","year":"2020","unstructured":"Izano MA, Lo JC, Adams AL, et al.. Bisphosphonate treatment beyond 5 years and hip fracture risk in older women. JAMA Netw Open. 2020, 3:e2025190. 10.1001\/jamanetworkopen.2020.25190","journal-title":"JAMA Netw Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0506-x","article-title":"Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women","volume":"19","author":"Rabenda V","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V, et al.. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008, 19:811-8. 10.1007\/s00198-007-0506-x","journal-title":"Osteoporos Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","volume":"58","author":"Eriksen EF","year":"2014","unstructured":"Eriksen EF, D\u00edez-P\u00e9rez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014, 58:126-35. 10.1016\/j.bone.2013.09.023","journal-title":"Bone"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.03.2271","article-title":"Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates","volume":"123","author":"Cole RE","year":"2011","unstructured":"Cole RE. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates. Postgrad Med. 2011, 123:131-44. 10.3810\/pgm.2011.03.2271","journal-title":"Postgrad Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313195-efficacy-of-bisphosphonates-in-reducing-fracture-risk-among-postmenopausal-women-with-osteoporosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:17:23Z","timestamp":1732688243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313195-efficacy-of-bisphosphonates-in-reducing-fracture-risk-among-postmenopausal-women-with-osteoporosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.74542","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}